Neurocrine Biosciences
NBIX
511 hedge funds and large institutions have $10.4B invested in Neurocrine Biosciences in 2023 Q3 according to their latest regulatory filings, with 90 funds opening new positions, 158 increasing their positions, 198 reducing their positions, and 30 closing their positions.
200% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 30
30% more call options, than puts
Call options by funds: $71.2M | Put options by funds: $54.7M
19% more capital invested
Capital invested by funds: $8.68B → $10.4B (+$1.69B)
12% more funds holding
Funds holding: 456 → 511 (+55)
0.01% more ownership
Funds ownership: 93.97% → 93.98% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
20% less repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 198
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$260M |
| 2 |
VRS
Virginia Retirement Systems
Richmond,
Virginia
|
+$48.1M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.2M |
| 4 |
Millennium Management
New York
|
+$44M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$33.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Amundi
Paris,
France
|
-$93.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$89.4M |
| 3 |
Man Group
London,
United Kingdom
|
-$66.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$60M |
| 5 |
AC
Armistice Capital
New York
|
-$45.7M |
NBIX Hedge Fund Activity: Q3 2023 in Review
511 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2023, worth a combined $10.4B — up 19% from $8.68B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new NBIX positions and 30 closed out — a net gain of 60 holders — while 158 added to existing stakes and 198 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $260M. The largest seller was Amundi, cutting an estimated $93.2M.
- 511 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2023, up from 456 in Q2 2023.
- Funds reported $10.4B of Neurocrine Biosciences stock for Q3 2023, up 19% quarter-over-quarter.
- 90 funds opened new Neurocrine Biosciences positions in Q3 2023 and 30 closed out, a net change of +60 holders.
- The largest Neurocrine Biosciences buyer in Q3 2023 was Point72 Asset Management, an estimated $260M added.
- The largest Neurocrine Biosciences seller in Q3 2023 was Amundi, an estimated $93.2M sold.
Based on aggregated 13F filings for Q3 2023.